DSM has reported what it describes as a good year. Group sales were up 2%; adjusted EBITDA was up 10%.

Nutrition sales were ahead 5%, with organic sales increasing 2%. Adjusted EBITDA was up 12%. Net profit was €764m, with adjusted net profit €830m, up 8% versus underlying business in 2018.

Feike Sijbesma, outgoing CEO, Geraldine Matchett and Dimitri de Vreeze, incoming Co-CEOs, said: “We are pleased to have delivered a good financial performance, as well as achieving our key milestones in the first year of Strategy 2021. Given the softer trading conditions seen in some of our markets, we are focused on driving growth, costs and operational excellence initiatives across the company to offset these adverse macro-economic conditions. Our outlook for 2020 is based on our own strength and self-help actions, and underlines our commitment to DSM’s Strategy 2021 targets. Our businesses are well positioned to capitalize on many strong fundamental growth drivers related to the world’s most pressing challenges and we expect our large innovation programs to begin to contribute in 2020, and further expand during 2021 and beyond.”

DSM says it expects to deliver a mid-single digit increase in Adjusted EBITDA for 2020 compared to prior year, together with an improvement in Adjusted Net Operating Free Cash Flow in line with our Strategy 2021 targets. This outlook is driven by DSM’s own growth initiatives, innovation programs and self-help actions, and does not assume any significant improvement to the current macro-economic environment.